Inhibikase IKT (Parkinson's) MK $33Mio -> 5Mrd+ bis Ende 2023(?!) (Seite 3)
eröffnet am 24.01.22 11:02:17 von
neuester Beitrag 16.05.24 05:02:15 von
neuester Beitrag 16.05.24 05:02:15 von
Beiträge: 28
ID: 1.356.796
ID: 1.356.796
Aufrufe heute: 3
Gesamt: 2.612
Gesamt: 2.612
Aktive User: 0
ISIN: US45719W1062 · WKN: A2QAMK · Symbol: IQT
0,5500
EUR
-16,67 %
-0,1100 EUR
Letzter Kurs 30.06.23 Frankfurt
Werte aus der Branche Finanzdienstleistungen
Wertpapier | Kurs | Perf. % |
---|---|---|
0,5080 | +102,39 | |
2,2600 | +50,67 | |
11,950 | +49,37 | |
1,3400 | +41,05 | |
7,5000 | +28,21 |
Wertpapier | Kurs | Perf. % |
---|---|---|
1,1000 | -14,73 | |
26,00 | -16,13 | |
1,0000 | -16,67 | |
25,00 | -37,50 | |
10,500 | -39,38 |
Beitrag zu dieser Diskussion schreiben
Top Reactions
The Amazing Creskin DANKE
Catalysts:
Before end of June:
- 20+ requisite P2/3 testing sites contracted.
- P2 dosing begins
- P1b results
- Journal publication describing MOA in more detail and how IkT-148009 with RAMP works to stop, clear, and partially reverse PD (rejuvenate dead neurons) in more than half of PD patients.
Before end of Q3:
- Animal studies complete on multiple systems atrophy (MSA).
- Announcement for P2 for MSA.
- IND submission for 001Pro for stable phase chronic myelogenous leukemia (CML).
Before end of 2022:
- partial results for 148009 for PD
- partnership for 001Pro
- dosing for P2 for MSA
An effective treatment for MSA alone is easily worth $1Billion market cap.
https://finance.yahoo.com/quote/IKT/community?p=IKT#:~:text=…
The Amazing Creskin DANKE
Why is $IKT's 148009 superior other enzyme inhibitors, such as Imatinib, Dasatinib, and Nilotinib? Because only 148009 targets c-Abl1 and c-Abl2/Arg WITHOUT inhibiting c-Kit, PDGFRa, and PDGFRb. Inhibiting c-Kit, PDGFRa, and PDGFRb results in toxicity.
IkT-148009 will be shown to be safe (this quarter) and effective in humans (within 12 months)
.https://finance.yahoo.com/quote/IKT/community?p=IKT#:~:text=…
The Amazing Creskin DANKE
Catalysts:
Before end of June:
- 20+ requisite P2/3 testing sites contracted.
- P2 dosing begins
- P1b results
- Journal publication describing MOA in more detail and how IkT-148009 with RAMP works to stop, clear, and partially reverse PD (rejuvenate dead neurons) in more than half of PD patients.
Before end of Q3:
- Animal studies complete on multiple systems atrophy (MSA).
- Announcement for P2 for MSA.
- IND submission for 001Pro for stable phase chronic myelogenous leukemia (CML).
Before end of 2022:
- partial results for 148009 for PD
- partnership for 001Pro
- dosing for P2 for MSA
An effective treatment for MSA alone is easily worth $1Billion market cap.
https://finance.yahoo.com/quote/IKT/community?p=IKT#:~:text=…
The Amazing Creskin DANKE
Why is $IKT's 148009 superior other enzyme inhibitors, such as Imatinib, Dasatinib, and Nilotinib? Because only 148009 targets c-Abl1 and c-Abl2/Arg WITHOUT inhibiting c-Kit, PDGFRa, and PDGFRb. Inhibiting c-Kit, PDGFRa, and PDGFRb results in toxicity.
IkT-148009 will be shown to be safe (this quarter) and effective in humans (within 12 months)
.https://finance.yahoo.com/quote/IKT/community?p=IKT#:~:text=…
mikedar
11:50 AM
$IKT
IKT has some qualified Managers
Roger Rush, Ph.D.
Preclinical Project Management
From March 2012 to December 2014, he was Vice President, Preclinical Development for Idenix Pharmaceuticals, Inc., a wholly owned subsidiary of Merck & Company, Inc., where he managed the DMPK, toxicology, and discovery research that led to the identification of lead molecules to treat Hepatitis C virus.
Idenix Pharmaceuticals, Inc., bought out by Merck & Company, Inc
The transaction, valued the purchase of Idenix at approximately $3.85 billion.
$3.85 billion/30 mill IKT share count current is 128$ a share... just saying... a little potential????
https://stocktwits.com/mikedar/message/450185809
11:50 AM
$IKT
IKT has some qualified Managers
Roger Rush, Ph.D.
Preclinical Project Management
From March 2012 to December 2014, he was Vice President, Preclinical Development for Idenix Pharmaceuticals, Inc., a wholly owned subsidiary of Merck & Company, Inc., where he managed the DMPK, toxicology, and discovery research that led to the identification of lead molecules to treat Hepatitis C virus.
Idenix Pharmaceuticals, Inc., bought out by Merck & Company, Inc
The transaction, valued the purchase of Idenix at approximately $3.85 billion.
$3.85 billion/30 mill IKT share count current is 128$ a share... just saying... a little potential????
https://stocktwits.com/mikedar/message/450185809
Ein eher kritischer Begleiter auf Stocktwits, aber hier gehe ich voll mit:
soufre88 04:19 PM
Dr. Werner is a brilliant, eminently qualified scientist, however I would like to see him bring in some Industry/Pharma help.
I know he has said no to a partnership before phase 2, but I believe he should reconsider that. If he can get a deal like Novartis gave UCB ($150m upfront, $1.5b biobucks) a few months ago for their small molecule a-syn inhibitor(w/ only phase 1b data in hand) he should consider it to derisk his exposure.
https://stocktwits.com/soufre88/message/436816617
"Novartis has seen enough promise in the early data to write UCB a check. In return for a $150 million upfront payment, and the promise of much more down the line, Novartis has secured the right to co-develop and co-commercialize UCB0599. UCB will take the lead commercially in Europe and Japan, leaving Novartis to handle the U.S. and all other territories."
https://www.fiercebiotech.com/biotech/alpha-challenger-novar…
soufre88 04:19 PM
Dr. Werner is a brilliant, eminently qualified scientist, however I would like to see him bring in some Industry/Pharma help.
I know he has said no to a partnership before phase 2, but I believe he should reconsider that. If he can get a deal like Novartis gave UCB ($150m upfront, $1.5b biobucks) a few months ago for their small molecule a-syn inhibitor(w/ only phase 1b data in hand) he should consider it to derisk his exposure.
https://stocktwits.com/soufre88/message/436816617
"Novartis has seen enough promise in the early data to write UCB a check. In return for a $150 million upfront payment, and the promise of much more down the line, Novartis has secured the right to co-develop and co-commercialize UCB0599. UCB will take the lead commercially in Europe and Japan, leaving Novartis to handle the U.S. and all other territories."
https://www.fiercebiotech.com/biotech/alpha-challenger-novar…
Abl Kinase Inhibition: Disease Modifying Strategy For Parkinson’s Disease
Antwort auf Beitrag Nr.: 70.614.961 von soulist am 24.01.22 11:02:17
Inhibikase Therapeutics
@inhibikase
Inhibikase's Prodrug technology is a technology platform that enables greater control over non-hematological side effects common to kinase inhibitor therapies, such as nausea or diarrhea, and may improve drug delivery into the target tissue. https://bit.ly/2ZLven4 $IKT
Original (Englisch) übersetzt
Die Prodrug-Technologie von Inhibikase ist eine Technologieplattform, die eine bessere Kontrolle über nicht-hämatologische Nebenwirkungen ermöglicht, die bei Therapien mit Kinase-Inhibitoren üblich sind, wie Übelkeit oder Durchfall und die Arzneimittelabgabe in das Zielgewebe verbessern kann.
https://www.inhibikase.com/about
@inhibikase
Inhibikase's Prodrug technology is a technology platform that enables greater control over non-hematological side effects common to kinase inhibitor therapies, such as nausea or diarrhea, and may improve drug delivery into the target tissue. https://bit.ly/2ZLven4 $IKT
Original (Englisch) übersetzt
Die Prodrug-Technologie von Inhibikase ist eine Technologieplattform, die eine bessere Kontrolle über nicht-hämatologische Nebenwirkungen ermöglicht, die bei Therapien mit Kinase-Inhibitoren üblich sind, wie Übelkeit oder Durchfall und die Arzneimittelabgabe in das Zielgewebe verbessern kann.
https://www.inhibikase.com/about
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders (z.b. Alzeimer)
1Q 2022 BUSINESS PRESENTATION
https://d1io3yog0oux5.cloudfront.net/_5ce61bdbf47e2aa9222f22…
$33 Mio Marktkapitalisierung
$44 Mio Cash (genug um uns durchP2 zu bringen und praktisch schuldenfrei)
Common Shares Outstanding 25,177,051 (January 4, 2022)
Options (WAEP: $2.47)3,580,952
Warrants (WAEP: $5.21) 1,561,913
Fully Diluted Shares Outstanding 30,319,916
Insider Ownership Percentage: 55.80%
Insider Buying (Last 12 Months): $46,470.33 (zu $2 30% über damaligen Aktienkurs)
Insider Selling (Last 12 Months): $0.00
insidertrades.com/inhibikase-therapeutics-inc-stock/
34 funds or institutions reporting positions in Inhibikase Therapeutics Inc. This represents an increase of 8 owner(s) and 30.77 percent in the last three months.
Total shares owned by institutions increased in the last three months to 4,169,757 shares. fintel.io/news/...bikase-therapeutics-inc-0.37647418272841804
Bei Insider ownership von 55,8%, sind also lediglich 6,88 Mio Shares im free float.
"Certainly doesn’t take many shares to push this puppy up can’t imagine when positive news actually is released what it would do."
Dr. Milton Werner zum Thema ab 1:24:41
"At what shareprice would you sell?"
Er macht kein Geheimnis draus, dass nach erfolgreicher Phase 2 die ganze Geschichte verkauft wird, um das Medikament auf schnellsten Wege zu den Patienten zu bringen.
"...finding reasons to sell after successful P2 results. First it was the joke in a previous interview about how he would be fired for not taking a buyout offer. Now it’s a strategy: fastest route to patient. Everything’s set for phase 2 and the value is unrealized so push thru. He’s a one man show and would be unable to proceed efficiently by himself. If an EUA was granted after successful P2 big pharma could have that on the market in no time..."
Dr. Milton Werner Part I “...safety properties and selectivity that has never been seen in our view...”
Dr. Miilton Werner Part II “...the value of that drug (transformative drug IKT 148009) in our view is ASTRONOMICAL...“
Dr. Milton Werner Part III "...We’ve done a full commercial opportunity assessment, to us that means this is a product (transformative drug IKT 148009) that could earn between 9 and 13B a year at a 50% market share.”
$10 Mrd pro Jahr bei 50% Marktanteil - Dr.Werner spricht selbst euphorisch vom "holy grail"
A $5B sale of the company gives a share price of $150 at 30M shares fully diluted.
150 Dollar klingen weit entfernt bei einem Schlusskurs am Freitag von $1.32 - schaun wir mal, wie's ultimo 2023 aussieht.
Ist nicht lang hin...
1Q 2022 BUSINESS PRESENTATION
https://d1io3yog0oux5.cloudfront.net/_5ce61bdbf47e2aa9222f22…
$33 Mio Marktkapitalisierung
$44 Mio Cash (genug um uns durchP2 zu bringen und praktisch schuldenfrei)
Common Shares Outstanding 25,177,051 (January 4, 2022)
Options (WAEP: $2.47)3,580,952
Warrants (WAEP: $5.21) 1,561,913
Fully Diluted Shares Outstanding 30,319,916
Insider Ownership Percentage: 55.80%
Insider Buying (Last 12 Months): $46,470.33 (zu $2 30% über damaligen Aktienkurs)
Insider Selling (Last 12 Months): $0.00
insidertrades.com/inhibikase-therapeutics-inc-stock/
34 funds or institutions reporting positions in Inhibikase Therapeutics Inc. This represents an increase of 8 owner(s) and 30.77 percent in the last three months.
Total shares owned by institutions increased in the last three months to 4,169,757 shares. fintel.io/news/...bikase-therapeutics-inc-0.37647418272841804
Bei Insider ownership von 55,8%, sind also lediglich 6,88 Mio Shares im free float.
"Certainly doesn’t take many shares to push this puppy up can’t imagine when positive news actually is released what it would do."
Dr. Milton Werner zum Thema ab 1:24:41
"At what shareprice would you sell?"
Er macht kein Geheimnis draus, dass nach erfolgreicher Phase 2 die ganze Geschichte verkauft wird, um das Medikament auf schnellsten Wege zu den Patienten zu bringen.
"...finding reasons to sell after successful P2 results. First it was the joke in a previous interview about how he would be fired for not taking a buyout offer. Now it’s a strategy: fastest route to patient. Everything’s set for phase 2 and the value is unrealized so push thru. He’s a one man show and would be unable to proceed efficiently by himself. If an EUA was granted after successful P2 big pharma could have that on the market in no time..."
Dr. Milton Werner Part I “...safety properties and selectivity that has never been seen in our view...”
Dr. Miilton Werner Part II “...the value of that drug (transformative drug IKT 148009) in our view is ASTRONOMICAL...“
Dr. Milton Werner Part III "...We’ve done a full commercial opportunity assessment, to us that means this is a product (transformative drug IKT 148009) that could earn between 9 and 13B a year at a 50% market share.”
$10 Mrd pro Jahr bei 50% Marktanteil - Dr.Werner spricht selbst euphorisch vom "holy grail"
A $5B sale of the company gives a share price of $150 at 30M shares fully diluted.
150 Dollar klingen weit entfernt bei einem Schlusskurs am Freitag von $1.32 - schaun wir mal, wie's ultimo 2023 aussieht.
Ist nicht lang hin...